Demographic and clinical characteristics of the 323 patients diagnosed with AML, DLBCL or myeloma at the two HMRN study hospitals between May 2005 and April 2008 who died before May 2010
| All deaths (n=323) | All diagnoses (N=323) | AML (N=107) | DLBCL (N=102) | Myeloma (N=114) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Place of death discussion | Place of death discussion | Place of death discussion | Place of death discussion | ||||||
| Yes N (%) | No* N (%) | Yes N (%) | No* N (%) | Yes N (%) | No* N (%) | Yes N (%) | No* N (%) | ||
| Total | 323 (100) | 142 (100) | 181 (100) | 49 (100) | 58 (100) | 43 (100) | 59 (100) | 50 (100) | 64 (100) |
| Sex | |||||||||
| Male | 178 (55.1) | 76 (53.5) | 102 (56.4) | 27 (55.1) | 34 (58.6) | 17 (39.5) | 29 (49.2) | 32 (64.0) | 39 (60.9) |
| Female | 145 (44.9) | 66 (46.5) | 79 (43.6) | 22 (44.9) | 24 (41.4) | 26 (60.5) | 30 (50.8) | 18 (36.0) | 25 (39.1) |
| Age at diagnosis | |||||||||
| ≤60 | 58 (17.9) | 25 (17.6) | 33 (18.2) | 9 (18.4) | 16 (27.6) | 9 (20.9) | 9 (15.2) | 7 (14.0) | 8 (12.5) |
| 61–74 | 122 (37.8) | 50 (35.2) | 72 (39.8) | 16 (32.6) | 23 (39.7) | 13 (30.2) | 26 (44.1) | 21 (42.0) | 23 (35.9) |
| 75+ | 143 (44.3) | 67 (47.2) | 76 (42.0) | 24 (49.0) | 19 (32.8) | 21 (48.8) | 24 (40.7) | 22 (44.0) | 33 (51.6) |
| Mean (SD) | 71.5 (12.8) | 71.9 (12.6) | 71.2 (13.0) | 71.7 (13.9) | 66.5 (14.4) | 71.3 (13.5) | 73.0 (13.3) | 72.5 (10.4) | 73.9 (10.1) |
| Age at death | |||||||||
| ≤60 | 53 (16.4) | 23 (16.2) | 30 (16.6) | 8 (16.3) | 16 (27.6) | 8 (18.6) | 8 (13.5) | 7 (14.0) | 6 (9.4) |
| 61–74 | 117 (36.2) | 49 (34.5) | 68 (37.6) | 16 (32.7) | 22 (37.9) | 14 (32.6) | 25 (42.4) | 19 (14.0) | 21 (32.8) |
| 75+ | 153 (47.4) | 70 (49.3) | 83 (45.8) | 25 (51.0) | 20 (34.5) | 21 (48.8) | 26 (44.1) | 24 (48.0) | 37 (57.8) |
| Mean (SD) | 72.4 (12.7) | 72.8 (12.3) | 72.0 (13.0) | 72.2 (13.8) | 67.2 (14.2) | 72.2 (13.3) | 73.6 (13.4) | 73.9 (10.0) | 75.0 (10.0) |
| Time from diagnosis to death (months) | |||||||||
| ≤1 | 75 (23.2) | 21 (14.8) | 54 (29.8) | 10 (20.4) | 20 (34.4) | 9 (20.9) | 23 (39.0) | 2 (4.0) | 11 (17.2) |
| 1–6 | 83 (25.7) | 35 (24.7) | 48 (26.5) | 19 (38.8) | 16 (27.6) | 9 (20.9) | 18 (30.5) | 7 (14.0) | 14 (21.9) |
| 6–12 | 62 (19.2) | 33 (23.2) | 29 (16.1) | 13 (26.5) | 11 (19.0) | 11 (25.6) | 5 (8.5) | 9 (18.0) | 13 (20.3) |
| 12+ | 103 (31.9) | 53 (37.3) | 50 (27.6) | 7 (14.3) | 11 (19.0) | 14 (32.6) | 13 (22.0) | 32 (64.0) | 26 (40.6) |
| Mean (SD) | 10.6 (12.0) | 11.8 (11.6) | 9.7 (12.2) | 5.9 (6.1) | 7.4 (9.8) | 10.6 (11.2) | 7.7 (12.1) | 18.6 (12.6) | 13.5 (13.5) |
| Place of death | |||||||||
| Hospital | 240 (74.3) | 88 (62.0) | 152 (84.0) | 28 (57.1) | 53 (91.4) | 28 (65.1) | 50 (84.7) | 32 (64.0) | 49 (76.6) |
| Home | 49 (15.2) | 34 (23.9) | 15 (8.3) | 13 (26.5) | 3 (5.2) | 10 (23.3) | 5 (8.5) | 11 (22.0) | 7 (10.9) |
| Hospice | 18 (5.6) | 13 (9.2) | 5 (2.8) | 6 (12.3) | 1 (1.7) | 4 (9.3) | 2 (3.4) | 3 (6.0) | 2 (3.1) |
| Nursing home | 16 (4.9) | 7 (4.9) | 9 (4.9) | 2 (4.1) | 1 (1.7) | 1 (2.3) | 2 (3.4) | 4 (8.0) | 6 (9.4) |
*No evidence of a discussion about preferred place of death could be found in medical records.
AML, acute myeloid leukaemia; DLBCL, diffuse large B-cell lymphoma; HMRN, Haematological Malignancy Research Network.